The U.S. Food and Drug Administration (FDA) has approved the use of and granted the ''Breakthrough Therapy Designation'' to the drug acalabrutinib for the treatment of adults with mantle cell lymphoma who have received at least one prior treatment. The oral drug will be useful for patients who did not respond to an earlier treatment or the cancer has relapsed following treatment, often leaving them with no other treatment option.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer